1Centre for Ocular Research & Education (CORE), University of Waterloo School of Optometry & Vision Science, Waterloo, Ontario, Canada
2Nature's Way Canada, Dartmouth, Nova Scotia, Canada
3Centre for Eye and Vision Research (CEVR), Hung Hom, Kowloon, Hong Kong
∗[email protected]
Submitted: February 20, 2021
Accepted: September 6, 2021
Funding/Support: Nature's Way of Canada (Industry funding; to LWJ).
Conflict of Interest Disclosure: TJ and JSR are employees of Nature's Way of Canada (the Sponsor of the trial). The sponsor provided financial and material support. The sponsor provided comment on the study design, analysis, and interpretation. The authors were responsible for the preparation of the manuscript and the decision to submit this article for publication. Each of the authors had full access to the study data and takes full responsibility for the presentation in this article. CORE has received research support or lectureship honoraria from Alcon, Allergan, Allied Innovations, Aurinia Pharma, Azura Ophthalmics, Bausch Health Canada, BHVI, Canadian Association of Optometrists, CFI, CIHR, CooperVision, GL Chemtec, Horizon 2020, i-Med Pharma, Johnson & Johnson Vision, Lubris, Menicon, Mitacs, Nature’s Way, NSERC, Novartis, Ophtecs, Oté Pharma, PS Therapy, Santen, SightGlass, SightSage and Visioneering Tech Inc.
Study Registration Information: Registration database: ClinicalTrials.gov. Registration number: NCT03265327.
Author Contributions and Acknowledgments: Conceptualization: AN, JW, LWJ; Formal Analysis: AN; Funding Acquisition: JW, LWJ; Investigation: AN, JW, LWJ; Methodology: AN, JW, LWJ; Project Administration: AN, JW; Resources: JW, TJ, LWJ, JSR; Writing – Original Draft: AN, JW, LWJ; Writing – Review & Editing: AN, JW, TJ, LWJ, JSR.
This work was presented as a poster at the American Academy of Optometry Annual Meeting, Orlando, Florida, in October 2019.
